Delivering extraordinary. Empowering ordinary.

We’re developing novel oral medicines for rare diseases to help patients take part in the everyday activities they enjoy.

Learn More

Structure-guided Drug Design

We combine traditional cell biology with medicinal chemistry to build synthetic compounds that bind to specific protein targets to fight disease.

See Our Science

We are developing a pipeline of oral drugs for rare diseases.

View Our Pipeline

Stay up to date with the latest discoveries, events, and reports from BioCryst.

January 26, 2023: BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema
January 23, 2023: BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe
January 9, 2023: BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

VIEW ALL PRESS RELEASES

We are a collection of passionate individuals united by a commitment to scientific excellence and an unwavering focus on the needs of patients.

JOB OPENINGS